Pfizer Inc. $PFE Shares Purchased by Teacher Retirement System of Texas

Teacher Retirement System of Texas grew its position in shares of Pfizer Inc. (NYSE:PFE) by 32.3% during the 3rd quarter, Holdings Channel reports. The firm owned 2,764,113 shares of the biopharmaceutical company’s stock after purchasing an additional 675,419 shares during the period. Teacher Retirement System of Texas’ holdings in Pfizer were worth $70,430,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of the company. Vanguard Group Inc. raised its position in Pfizer by 1.9% in the second quarter. Vanguard Group Inc. now owns 533,363,457 shares of the biopharmaceutical company’s stock worth $12,928,730,000 after acquiring an additional 10,198,330 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of Pfizer by 1.4% during the 2nd quarter. Geode Capital Management LLC now owns 127,471,481 shares of the biopharmaceutical company’s stock valued at $3,080,552,000 after purchasing an additional 1,820,634 shares in the last quarter. Norges Bank acquired a new position in shares of Pfizer in the 2nd quarter worth approximately $2,270,157,000. Charles Schwab Investment Management Inc. raised its holdings in shares of Pfizer by 2.4% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 49,165,032 shares of the biopharmaceutical company’s stock worth $1,191,760,000 after purchasing an additional 1,135,457 shares in the last quarter. Finally, Fisher Asset Management LLC lifted its stake in Pfizer by 2.0% during the second quarter. Fisher Asset Management LLC now owns 48,390,268 shares of the biopharmaceutical company’s stock valued at $1,172,980,000 after purchasing an additional 950,239 shares during the last quarter. Institutional investors own 68.36% of the company’s stock.

Pfizer Stock Performance

Shares of Pfizer stock opened at $26.09 on Friday. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $27.69. The company has a quick ratio of 0.97, a current ratio of 1.28 and a debt-to-equity ratio of 0.62. The stock has a market cap of $148.34 billion, a PE ratio of 15.17 and a beta of 0.47. The business has a fifty day simple moving average of $25.39 and a 200-day simple moving average of $25.01.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.79 by $0.08. Pfizer had a return on equity of 20.17% and a net margin of 15.65%.The firm had revenue of $16.65 billion during the quarter, compared to the consensus estimate of $16.94 billion. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. On average, sell-side analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, January 23rd will be given a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.6%. The ex-dividend date of this dividend is Friday, January 23rd. Pfizer’s dividend payout ratio is 100.00%.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on PFE shares. Wall Street Zen cut shares of Pfizer from a “buy” rating to a “hold” rating in a report on Sunday, September 28th. Wolfe Research set a $24.00 price objective on Pfizer and gave the stock an “underperform” rating in a research note on Wednesday, December 17th. Scotiabank began coverage on Pfizer in a report on Thursday, November 13th. They issued a “sector outperform” rating and a $30.00 target price on the stock. Citigroup assumed coverage on Pfizer in a research report on Tuesday, December 2nd. They set a “neutral” rating and a $26.00 target price on the stock. Finally, TD Cowen reiterated a “hold” rating on shares of Pfizer in a research report on Tuesday, December 30th. Two analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, twelve have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $27.88.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.